Novel therapeutic approaches for targeting tumor angiogenesis

Anticancer Research

Volumn 32, Issue 1, 2012, Pages 1-12

  Linkous, Amanda G ^a   Yazlovitskaya, Eugenia M ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Angiogenesis; Cancer; cPLA2; Lysophospholipids; Review; VEGF

Indexed keywords

3 DEAZANEPLANOCIN A; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; AXITINIB; BEVACIZUMAB; CEDIRANIB; CRT0066101; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; ESTROGEN RECEPTOR ALPHA; FASUDIL; GLYCOPROTEIN; GUANOSINE TRIPHOSPHATASE; PHOSPHOLIPASE C BETA3; PLATELET DERIVED GROWTH FACTOR; POLYCYSTIN 1; PROTEIN KINASE D; PROTEIN P53; RAS PROTEIN; ROSCOVITINE; SORAFENIB; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; THROMBOSPONDIN 1; TIVOZANIB; TRANSCRIPTION FACTOR EZH2; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CELL PROLIFERATION; COLON CANCER; DIARRHEA; DOWN REGULATION; FATIGUE; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HAND FOOT AND MOUTH DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NASOPHARYNX CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; T CELL LYMPHOMA; THYROID DISEASE; TUMOR; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR GROWTH; UPREGULATION; VOMITING;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84855669275     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996. (Pubitemid 26272076)
2. Chung AS, Lee J and Ferrara N: Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10: 505-514, 2010.
3. Rastinejad F, Polverini PJ and Bouck NP: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56: 345-355, 1989. (Pubitemid 19052652)
4. Ellis LM and Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591, 2008.
5. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005. (Pubitemid 46202320)
6. Norden AD, Drappatz J and Wen PY: Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5: 610-620, 2009.
7. Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH and Chauffert B: Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris) 164: 588-594, 2008. (Pubitemid 351902232)
8. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P and Gruber ML: Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110: 173-180, 2009.
9. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R and Cloughesy TF: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72: 1217-1222, 2009.
10. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S and Wen PY: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787, 2008.
11. Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M and Lassen U: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 48: 52-58, 2009.
12. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91: 329-336, 2009.
13. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY and Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147, 2004. (Pubitemid 38524883)
14. Bergers G and Hanahan D: Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 8: 592-603, 2008.
15. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY and Jain RK: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95, 2007. (Pubitemid 46075199)
16. Chen Z, Htay A, Dos Santos W, Gillies GT, Fillmore HL, Sholley MM and Broaddus WC: In vitro angiogenesis by human umbilical vein endothelial cells (HUVEC) induced by three-dimensional co-culture with glioblastoma cells. J Neurooncol 92: 121-128, 2009.
17. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM and Lassman AB: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73: 1200-1206, 2009.
18. Aghi M, Cohen KS, Klein RJ, Scadden DT and Chiocca EA: Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 66: 9054-9064, 2006. (Pubitemid 44521124)
19. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z and Bergers G: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13: 206-220, 2008. (Pubitemid 351318372)
20. Allt G and Lawrenson JG: Pericytes: cell biology and pathology. Cells Tissues Organs 169: 1-11, 2001. (Pubitemid 32437039)
21. Bergers G and Song S: The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 7: 452-464, 2005. (Pubitemid 41555617)
22. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS and Bergers G: The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4: 133-146, 2003. (Pubitemid 37040829)
23. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF and Shuman MA: Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2: 306-314, 2000.
24. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
25. Sessa C, Guibal A, Del Conte G and Ruegg C: Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 5: 378-391, 2008. (Pubitemid 351958963)
26. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ and Rini BI: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24, 2006. (Pubitemid 46630489)
27. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M and Lauwers GY: Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase 1 trial in rectal cancer patients. J Clin Oncol 23: 8136-8139, 2005. (Pubitemid 46657433)
28. Shih TT, Hou HA, Liu CY, Chen BB, Tang JL, Chen HY, Wei SY, Yao M, Huang SY, Chou WC, Hsu SC, Tsay W, Yu CW, Hsu CY, Tien HF and Yang PC: Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 113: 3161-3167, 2009.
29. Barrett T, Brechbiel M, Bernardo M and Choyke PL: MRI of tumor angiogenesis. J Magn Reson Imaging 26: 235-249, 2007. (Pubitemid 47257720)
30. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J and McSheehy PM: Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 57: 761-771, 2006.
31. Smeenge M, Mischi M, Laguna Pes MP, de la Rosette JJ and Wijkstra H: Novel contrast-enhanced ultrasound imaging in prostate cancer. World J Urol 29: 581-587, 2011.
32. Wang J, Lv F, Fei X, Cui Q, Wang L, Gao X, Yuan Z, Lin Q, Lv Y and Liu A: Study on the characteristics of contrast-enhanced ultrasound and its utility in assessing the microvessel density in ovarian tumors or tumor-like lesions. Int J Biol Sci 7: 600-606, 2011.
33. Williams R, Hudson JM, Lloyd BA, Sureshkumar AR, Lueck G, Milot L, Atri M, Bjarnason GA and Burns PN: Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology 260: 581-590, 2011.
34. Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A and Escudier BJ: Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 16: 1216-1225, 2010.
35. Bhargava P and Robinson MO: Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 13: 103-111, 2011.
36. LaValle CR, George KM, Shadow ER, Lazo JS, Wipf P and Wang QJ: Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta 1806: 183-192, 2010.
37. Ha CH and Jin ZG: Protein kinase D1, a new molecular player in VEGF signaling and angiogenesis. Mol Cells 28: 1-5, 2009.
38. van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM and Byrne AT: The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug Discov Today 16: 219-228, 2011.
39. Linkous A, Geng L, Lyshchik A, Hallahan DE and Yazlovitskaya EM: Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. Clin Cancer Res 15: 1635-1644, 2009.
40. Schulte RR, Linkous AG, Hallahan DE and Yazlovitskaya EM: Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer. Cancer Lett 304: 137-143, 2011.
41. Yazlovitskaya EM, Linkous AG, Thotala DK, Cuneo KC and Hallahan DE: Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium. Cell Death Differ 15: 1641-1653, 2008.
42. Linkous AG, Yazlovitskaya EM and Hallahan DE: Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst 102: 1398-1412, 2010.
43. Folkman J: A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression. J Natl Cancer Inst 93: 734-735, 2001.
44. Herbert SP, Odell AF, Ponnambalam S and Walker JH: Activation of cytosolic phospholipase A2-α as a novel mechanism regulating endothelial cell cycle progression and angiogenesis. J Biol Chem 284: 5784-5796, 2009.
45. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T and Arai H: Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 281: 17492-17500, 2006.
46. Ptaszynska MM, Pendrak ML, Stracke ML and Roberts DD: Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res 8: 309-321, 2008.
47. Farooqui AA, Ong WY and Horrocks LA: Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 58: 591-620, 2006. (Pubitemid 44403685)
48. McKew JC, Foley MA, Thakker P, Behnke ML, Lovering FE, Sum FW, Tam S, Wu K, Shen MW, Zhang W, Gonzalez M, Liu S, Mahadevan A, Sard H, Khor SP and Clark JD: Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization. J Med Chem 49: 135-158, 2006. (Pubitemid 43077328)
49. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, Rose TM, Prestwich GD and Xu Y: Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 66: 3006-3014, 2006.
50. Aoki J, Inoue A and Okudaira S: Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781: 513-518, 2008.
51. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J and Arai H: Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 279: 17634-17639, 2004. (Pubitemid 38560528)
52. Jansen S, Stefan C, Creemers JW, Waelkens E, Van Eynde A, Stalmans W and Bollen M: Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci 118: 3081-3089, 2005. (Pubitemid 41149912)
53. Tokumura A, Miyake M, Yoshimoto O, Shimizu M and Fukuzawa K: Metal-ion stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma. Lipids 33: 1009-1015, 1998. (Pubitemid 28516479)
54. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J and Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158: 227-233, 2002.
55. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E and Liotta LA: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267: 2524-2529, 1992.
56. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J and Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281: 25822-25830, 2006. (Pubitemid 44401970)
57. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J and Mills GB: Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582: 257-264, 2002. (Pubitemid 34634137)
58. Hoeglund AB, Howard AL, Wanjala IW, Pham TC, Parrill AL and Baker DL: Characterization of non-lipid autotaxin inhibitors. Bioorg Med Chem 18: 769-776, 2010.
59. Clair T, Koh E, Ptaszynska M, Bandle RW, Liotta LA, Schiffmann E and Stracke ML: L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin. Lipids Health Dis 4: 5, 2005.
60. Keller TH, Pichota A and Yin Z: A practical view of 'druggability'. Curr Opin Chem Biol 10: 357-361, 2006.
61. Parrill AL and Baker DL: Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts. Expert Opin Ther Pat 20: 1619-1625, 2010.
62. Im DS: Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin 31: 1213-1222, 2010.
63. Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G and Serban M: Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta 1781: 588-594, 2008.
64. Xu X and Prestwich GD: Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 116: 1739-1750, 2010.
65. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, Fells JI, Perygin D, Parrill AL, Tigyi G and Prestwich GD: Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 69: 5441-5449, 2009.
66. Schleicher SM, Thotala DK, Linkous AG, Hu R, Leahy KM, Yazlovitskaya EM and Hallahan DE: Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS One 6: e22182, 2011.
67. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G and Sood AK: Regulation of tumor angiogenesis by EZH2. Cancer Cell 18: 185-197, 2010.
68. Chase A and Cross NC: Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613-2618, 2011.
69. Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T, Tanaka S, Tada M, Kanai F, Imazeki F, Iwama A and Yokosuka O: 3-deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer, 2011 Jun 29. [Epub ahead of print].
70. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE and Bhalla KN: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733-2743, 2009.
71. Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, Ikeda H, Nimura Y, Nagino M and Nakanuma Y: Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 101: 355-362, 2010.
72. Baker SJ: A role for Cdk4 in angiogenesis. Cell Cycle 9: 2493, 2010.
73. Liebl J, Krystof V, Vereb G, Takacs L, Strnad M, Pechan P, Havlicek L, Zatloukal M, Furst R, Vollmar AM and Zahler S: Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases. Angiogenesis 14: 281-291, 2011.
74. Liebl J, Weitensteiner SB, Vereb G, Takacs L, Furst R, Vollmar AM and Zahler S: Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J Biol Chem 285: 35932-35943, 2010.
75. Wesierska-Gadek J, Gritsch D, Zulehner N, Komina O and Maurer M: Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-alpha in human ER-positive breast cancer cells. J Cell Biochem 112: 761-772, 2011.
76. Abedin ZR, Ma Z and Reddy EP: Increased angiogenesis in Cdk4 (R24C/R24C):Apc (+/Min) intestinal tumors. Cell Cycle 9: 2456-2463, 2010.